Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyOsanetant
Identification
- Name
- Osanetant
- Accession Number
- DB04872
- Type
- Small Molecule
- Groups
- Investigational
- Description
Developed by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System (CNS) disorders. In a review of its R&D portfolio, the company announced in August 2005 that it would cease any further development of osanetant. This follows an earlier decision to discontinue development of eplivanserin for schizophrenia.
- Structure
Structure for DB04872 (Osanetant)
- Synonyms
- Not Available
- External IDs
- SR 142801 / SR-142801 / SR142801
- Categories
- UNII
- K7G81N94DT
- CAS number
- 160492-56-8
- Weight
- Average: 606.625
Monoisotopic: 605.257582985 - Chemical Formula
- C35H41Cl2N3O2
- InChI Key
- DZOJBGLFWINFBF-UMSFTDKQSA-N
- InChI
- InChI=1S/C35H41Cl2N3O2/c1-27(41)38(2)35(29-13-7-4-8-14-29)19-23-39(24-20-35)21-9-17-34(30-15-16-31(36)32(37)25-30)18-10-22-40(26-34)33(42)28-11-5-3-6-12-28/h3-8,11-16,25H,9-10,17-24,26H2,1-2H3/t34-/m0/s1
- IUPAC Name
- N-(1-{3-[(3R)-1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl]propyl}-4-phenylpiperidin-4-yl)-N-methylacetamide
- SMILES
- CN(C(C)=O)C1(CCN(CCC[C@@]2(CCCN(C2)C(=O)C2=CC=CC=C2)C2=CC(Cl)=C(Cl)C=C2)CC1)C1=CC=CC=C1
Pharmacology
- Indication
Potential therapy for schizophrenia, depression and visceral pain.
- Pharmacodynamics
Osanetant is a neurokinin-3 (NK3) receptor antagonist. Preliminary clinical trials have demonstrated that osanetant is superior to placebo on global assessment of efficacy and measures of positive symptoms in schizophrenia.
- Mechanism of action
The mechanism of action of osanetant is uncertain at this point. Various preclinical data indicate that activation of NK3 receptors enhances the release of biogenic amines, including dopamine and serotonin. NK3 receptor antagonists could block NK3-receptor-mediated activation of these systems.
Target Actions Organism UNeuromedin-K receptor Not Available Human - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 2,5-Dimethoxy-4-ethylamphetamine Osanetant may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine. Experimental, Illicit 2,5-Dimethoxy-4-ethylthioamphetamine Osanetant may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine. Experimental 3,4-Methylenedioxyamphetamine Osanetant may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine. Experimental, Illicit 4-Bromo-2,5-dimethoxyamphetamine Osanetant may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine. Experimental, Illicit 7-Nitroindazole The risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Osanetant. Experimental Acepromazine The risk or severity of adverse effects can be increased when Acepromazine is combined with Osanetant. Approved, Vet Approved Aceprometazine The risk or severity of adverse effects can be increased when Aceprometazine is combined with Osanetant. Approved Adipiplon The risk or severity of adverse effects can be increased when Osanetant is combined with Adipiplon. Investigational Agomelatine The risk or severity of adverse effects can be increased when Osanetant is combined with Agomelatine. Approved, Investigational Alaproclate The risk or severity of adverse effects can be increased when Osanetant is combined with Alaproclate. Experimental Alfaxalone The risk or severity of adverse effects can be increased when Osanetant is combined with Alfaxalone. Vet Approved Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Osanetant. Approved, Illicit Allopregnanolone The risk or severity of adverse effects can be increased when Osanetant is combined with Allopregnanolone. Investigational Almotriptan The risk or severity of adverse effects can be increased when Almotriptan is combined with Osanetant. Approved, Investigational Alphacetylmethadol The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Osanetant. Experimental, Illicit Alphaprodine The risk or severity of adverse effects can be increased when Osanetant is combined with Alphaprodine. Illicit Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Osanetant. Approved, Illicit, Investigational Amisulpride Osanetant may increase the antipsychotic activities of Amisulpride. Approved, Investigational Amitriptyline The risk or severity of adverse effects can be increased when Amitriptyline is combined with Osanetant. Approved Amobarbital The risk or severity of adverse effects can be increased when Amobarbital is combined with Osanetant. Approved, Illicit Amoxapine The risk or severity of adverse effects can be increased when Amoxapine is combined with Osanetant. Approved Amperozide The risk or severity of adverse effects can be increased when Osanetant is combined with Amperozide. Experimental Amphetamine Osanetant may decrease the stimulatory activities of Amphetamine. Approved, Illicit, Investigational Aripiprazole The risk or severity of adverse effects can be increased when Aripiprazole is combined with Osanetant. Approved, Investigational Articaine The risk or severity of adverse effects can be increased when Osanetant is combined with Articaine. Approved Asenapine The risk or severity of adverse effects can be increased when Asenapine is combined with Osanetant. Approved Azaperone The risk or severity of adverse effects can be increased when Osanetant is combined with Azaperone. Investigational, Vet Approved Azelastine Osanetant may increase the central nervous system depressant (CNS depressant) activities of Azelastine. Approved Baclofen The risk or severity of adverse effects can be increased when Baclofen is combined with Osanetant. Approved Barbital The risk or severity of adverse effects can be increased when Barbital is combined with Osanetant. Illicit Benperidol The risk or severity of adverse effects can be increased when Osanetant is combined with Benperidol. Approved, Investigational Benzocaine The risk or severity of adverse effects can be increased when Benzocaine is combined with Osanetant. Approved, Investigational Benzphetamine Osanetant may decrease the stimulatory activities of Benzphetamine. Approved, Illicit Benzyl alcohol The risk or severity of adverse effects can be increased when Osanetant is combined with Benzyl alcohol. Approved Brexpiprazole The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Osanetant. Approved, Investigational Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Osanetant. Approved Bromazepam The risk or severity of adverse effects can be increased when Bromazepam is combined with Osanetant. Approved, Illicit, Investigational Bromisoval The risk or severity of adverse effects can be increased when Osanetant is combined with Bromisoval. Experimental Bromocriptine The risk or severity of adverse effects can be increased when Bromocriptine is combined with Osanetant. Approved, Investigational Bromperidol The risk or severity of adverse effects can be increased when Osanetant is combined with Bromperidol. Approved, Investigational Brompheniramine The risk or severity of adverse effects can be increased when Brompheniramine is combined with Osanetant. Approved Brotizolam The risk or severity of adverse effects can be increased when Osanetant is combined with Brotizolam. Approved, Investigational, Withdrawn Bupivacaine The risk or severity of adverse effects can be increased when Bupivacaine is combined with Osanetant. Approved, Investigational Buprenorphine Osanetant may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Approved, Illicit, Investigational, Vet Approved Buspirone The risk or severity of adverse effects can be increased when Buspirone is combined with Osanetant. Approved, Investigational Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Osanetant. Approved, Illicit Butacaine The risk or severity of adverse effects can be increased when Osanetant is combined with Butacaine. Vet Approved Butalbital The risk or severity of adverse effects can be increased when Butalbital is combined with Osanetant. Approved, Illicit Butamben The risk or severity of adverse effects can be increased when Osanetant is combined with Butamben. Approved, Withdrawn Butethal The risk or severity of adverse effects can be increased when Butethal is combined with Osanetant. Approved, Illicit Butorphanol The risk or severity of adverse effects can be increased when Butorphanol is combined with Osanetant. Approved, Illicit, Vet Approved Cabergoline The risk or severity of adverse effects can be increased when Cabergoline is combined with Osanetant. Approved Canertinib The risk or severity of adverse effects can be increased when Osanetant is combined with Canertinib. Investigational Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Osanetant. Approved, Investigational Carbinoxamine The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Osanetant. Approved Carfentanil The risk or severity of adverse effects can be increased when Carfentanil is combined with Osanetant. Illicit, Investigational, Vet Approved Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Osanetant. Approved Cetirizine The risk or severity of adverse effects can be increased when Cetirizine is combined with Osanetant. Approved Chloral hydrate The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Osanetant. Approved, Illicit, Investigational, Vet Approved Chlordiazepoxide The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Osanetant. Approved, Illicit, Investigational Chlormezanone The risk or severity of adverse effects can be increased when Chlormezanone is combined with Osanetant. Approved, Investigational, Withdrawn Chloroprocaine The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Osanetant. Approved Chlorphenamine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Osanetant. Approved Chlorphentermine Osanetant may decrease the stimulatory activities of Chlorphentermine. Illicit, Withdrawn Chlorpromazine The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Osanetant. Approved, Investigational, Vet Approved Chlorprothixene The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Osanetant. Approved, Investigational, Withdrawn Chlorzoxazone The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Osanetant. Approved Cinchocaine The risk or severity of adverse effects can be increased when Cinchocaine is combined with Osanetant. Approved, Vet Approved Citalopram The risk or severity of adverse effects can be increased when Osanetant is combined with Citalopram. Approved Clemastine The risk or severity of adverse effects can be increased when Clemastine is combined with Osanetant. Approved, Investigational Clidinium The risk or severity of adverse effects can be increased when Clidinium is combined with Osanetant. Approved Clobazam The risk or severity of adverse effects can be increased when Clobazam is combined with Osanetant. Approved, Illicit clomethiazole The risk or severity of adverse effects can be increased when Osanetant is combined with clomethiazole. Investigational Clomipramine The risk or severity of adverse effects can be increased when Clomipramine is combined with Osanetant. Approved, Investigational, Vet Approved Clonazepam The risk or severity of adverse effects can be increased when Clonazepam is combined with Osanetant. Approved, Illicit Clonidine The risk or severity of adverse effects can be increased when Clonidine is combined with Osanetant. Approved Clopenthixol The risk or severity of adverse effects can be increased when Osanetant is combined with Clopenthixol. Experimental Clorazepate The risk or severity of adverse effects can be increased when Clorazepate is combined with Osanetant. Approved, Illicit Clothiapine The risk or severity of adverse effects can be increased when Osanetant is combined with Clothiapine. Experimental Clozapine The risk or severity of adverse effects can be increased when Clozapine is combined with Osanetant. Approved Cocaine The risk or severity of adverse effects can be increased when Cocaine is combined with Osanetant. Approved, Illicit Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Osanetant. Approved, Illicit Cyclizine The risk or severity of adverse effects can be increased when Cyclizine is combined with Osanetant. Approved Cyclobenzaprine The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Osanetant. Approved Cyclopropane The risk or severity of adverse effects can be increased when Osanetant is combined with Cyclopropane. Experimental Cyproheptadine The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Osanetant. Approved Dantrolene The risk or severity of adverse effects can be increased when Dantrolene is combined with Osanetant. Approved, Investigational Dapiprazole The risk or severity of adverse effects can be increased when Dapiprazole is combined with Osanetant. Approved Dapoxetine The risk or severity of adverse effects can be increased when Osanetant is combined with Dapoxetine. Investigational Deramciclane The risk or severity of adverse effects can be increased when Osanetant is combined with Deramciclane. Investigational Desflurane The risk or severity of adverse effects can be increased when Desflurane is combined with Osanetant. Approved Desipramine The risk or severity of adverse effects can be increased when Desipramine is combined with Osanetant. Approved, Investigational Desloratadine The risk or severity of adverse effects can be increased when Desloratadine is combined with Osanetant. Approved, Investigational Desvenlafaxine The risk or severity of adverse effects can be increased when Osanetant is combined with Desvenlafaxine. Approved, Investigational Detomidine The risk or severity of adverse effects can be increased when Osanetant is combined with Detomidine. Vet Approved Deutetrabenazine The risk or severity of adverse effects can be increased when Osanetant is combined with Deutetrabenazine. Approved, Investigational Dexbrompheniramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Osanetant. Approved Dexmedetomidine The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Osanetant. Approved, Vet Approved Dextroamphetamine Osanetant may decrease the stimulatory activities of Dextroamphetamine. Approved, Illicit Dextromethorphan The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Osanetant. Approved Dextromoramide The risk or severity of adverse effects can be increased when Dextromoramide is combined with Osanetant. Experimental, Illicit Dextropropoxyphene The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Osanetant. Approved, Illicit, Investigational, Withdrawn Dezocine The risk or severity of adverse effects can be increased when Dezocine is combined with Osanetant. Approved, Investigational Diazepam The risk or severity of adverse effects can be increased when Diazepam is combined with Osanetant. Approved, Illicit, Investigational, Vet Approved Diethyl ether The risk or severity of adverse effects can be increased when Osanetant is combined with Diethyl ether. Experimental Diethylpropion Osanetant may decrease the stimulatory activities of Diethylpropion. Approved, Illicit Difenoxin The risk or severity of adverse effects can be increased when Difenoxin is combined with Osanetant. Approved, Illicit Dihydrocodeine The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Osanetant. Approved, Illicit Dihydroergotamine The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Osanetant. Approved, Investigational Dihydroetorphine The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Osanetant. Experimental, Illicit Dihydromorphine The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Osanetant. Experimental, Illicit Dimenhydrinate The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Osanetant. Approved Diphenhydramine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Osanetant. Approved, Investigational Diphenoxylate The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Osanetant. Approved, Illicit Dixyrazine The risk or severity of adverse effects can be increased when Osanetant is combined with Dixyrazine. Experimental Doramectin The risk or severity of adverse effects can be increased when Osanetant is combined with Doramectin. Vet Approved Doxepin The risk or severity of adverse effects can be increased when Doxepin is combined with Osanetant. Approved, Investigational Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Osanetant. Approved, Vet Approved DPDPE The risk or severity of adverse effects can be increased when Osanetant is combined with DPDPE. Experimental Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Osanetant. Approved, Illicit Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Osanetant. Approved, Vet Approved Drotebanol The risk or severity of adverse effects can be increased when Drotebanol is combined with Osanetant. Experimental, Illicit Duloxetine The risk or severity of adverse effects can be increased when Osanetant is combined with Duloxetine. Approved Dyclonine The risk or severity of adverse effects can be increased when Dyclonine is combined with Osanetant. Approved Ecgonine The risk or severity of adverse effects can be increased when Ecgonine is combined with Osanetant. Experimental, Illicit Ecopipam The risk or severity of adverse effects can be increased when Osanetant is combined with Ecopipam. Investigational Efavirenz The risk or severity of adverse effects can be increased when Efavirenz is combined with Osanetant. Approved, Investigational Eletriptan The risk or severity of adverse effects can be increased when Eletriptan is combined with Osanetant. Approved, Investigational Eltanolone The risk or severity of adverse effects can be increased when Osanetant is combined with Eltanolone. Investigational Enflurane The risk or severity of adverse effects can be increased when Enflurane is combined with Osanetant. Approved, Investigational, Vet Approved Entacapone The risk or severity of adverse effects can be increased when Entacapone is combined with Osanetant. Approved, Investigational Ergoloid mesylate The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Osanetant. Approved Ergonovine The risk or severity of adverse effects can be increased when Ergonovine is combined with Osanetant. Approved Ergotamine The risk or severity of adverse effects can be increased when Ergotamine is combined with Osanetant. Approved Escitalopram The risk or severity of adverse effects can be increased when Osanetant is combined with Escitalopram. Approved, Investigational Estazolam The risk or severity of adverse effects can be increased when Estazolam is combined with Osanetant. Approved, Illicit Eszopiclone The risk or severity of adverse effects can be increased when Eszopiclone is combined with Osanetant. Approved, Investigational Ethanol Osanetant may increase the central nervous system depressant (CNS depressant) activities of Ethanol. Approved Ethchlorvynol The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Osanetant. Approved, Illicit, Withdrawn Ethosuximide The risk or severity of adverse effects can be increased when Ethosuximide is combined with Osanetant. Approved Ethotoin The risk or severity of adverse effects can be increased when Ethotoin is combined with Osanetant. Approved Ethyl carbamate The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Osanetant. Withdrawn Ethyl chloride The risk or severity of adverse effects can be increased when Osanetant is combined with Ethyl chloride. Approved, Experimental, Investigational Ethyl loflazepate The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Osanetant. Approved, Illicit Ethylmorphine The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Osanetant. Approved, Illicit Etidocaine The risk or severity of adverse effects can be increased when Osanetant is combined with Etidocaine. Approved Etifoxine The risk or severity of adverse effects can be increased when Osanetant is combined with Etifoxine. Investigational, Withdrawn Etizolam The risk or severity of adverse effects can be increased when Osanetant is combined with Etizolam. Approved Etomidate The risk or severity of adverse effects can be increased when Etomidate is combined with Osanetant. Approved Etoperidone The risk or severity of adverse effects can be increased when Osanetant is combined with Etoperidone. Withdrawn Etorphine The risk or severity of adverse effects can be increased when Etorphine is combined with Osanetant. Illicit, Vet Approved Ezogabine The risk or severity of adverse effects can be increased when Ezogabine is combined with Osanetant. Approved, Investigational Felbamate The risk or severity of adverse effects can be increased when Felbamate is combined with Osanetant. Approved Fencamfamine The risk or severity of adverse effects can be increased when Fencamfamine is combined with Osanetant. Approved, Illicit, Withdrawn Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Osanetant. Approved, Illicit, Investigational, Vet Approved Fexofenadine The risk or severity of adverse effects can be increased when Fexofenadine is combined with Osanetant. Approved, Investigational Flibanserin The risk or severity of adverse effects can be increased when Flibanserin is combined with Osanetant. Approved, Investigational Fluanisone The risk or severity of adverse effects can be increased when Osanetant is combined with Fluanisone. Experimental Fludiazepam The risk or severity of adverse effects can be increased when Fludiazepam is combined with Osanetant. Approved, Illicit Flunarizine The risk or severity of adverse effects can be increased when Flunarizine is combined with Osanetant. Approved Flunitrazepam The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Osanetant. Approved, Illicit Fluoxetine The risk or severity of adverse effects can be increased when Osanetant is combined with Fluoxetine. Approved, Vet Approved Flupentixol The risk or severity of adverse effects can be increased when Flupentixol is combined with Osanetant. Approved, Investigational, Withdrawn Fluphenazine The risk or severity of adverse effects can be increased when Fluphenazine is combined with Osanetant. Approved Flurazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Osanetant. Approved, Illicit, Investigational Fluspirilene The risk or severity of adverse effects can be increased when Fluspirilene is combined with Osanetant. Approved, Investigational Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Osanetant. Approved Fluvoxamine The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Osanetant. Approved, Investigational Fosphenytoin The risk or severity of adverse effects can be increased when Fosphenytoin is combined with Osanetant. Approved, Investigational Fospropofol The risk or severity of adverse effects can be increased when Osanetant is combined with Fospropofol. Approved, Illicit, Investigational Frovatriptan The risk or severity of adverse effects can be increased when Frovatriptan is combined with Osanetant. Approved, Investigational Gabapentin The risk or severity of adverse effects can be increased when Gabapentin is combined with Osanetant. Approved, Investigational Gabapentin Enacarbil The risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Osanetant. Approved, Investigational Gamma Hydroxybutyric Acid The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Osanetant. Approved, Illicit, Investigational Gepefrine Osanetant may decrease the stimulatory activities of Gepefrine. Experimental Gepirone The risk or severity of adverse effects can be increased when Osanetant is combined with Gepirone. Investigational Glutethimide The risk or severity of adverse effects can be increased when Glutethimide is combined with Osanetant. Approved, Illicit Guanfacine The risk or severity of adverse effects can be increased when Guanfacine is combined with Osanetant. Approved, Investigational Halazepam The risk or severity of adverse effects can be increased when Halazepam is combined with Osanetant. Approved, Illicit, Withdrawn Haloperidol The risk or severity of adverse effects can be increased when Haloperidol is combined with Osanetant. Approved Halothane The risk or severity of adverse effects can be increased when Halothane is combined with Osanetant. Approved, Vet Approved Heroin The risk or severity of adverse effects can be increased when Heroin is combined with Osanetant. Approved, Illicit, Investigational Hexobarbital The risk or severity of adverse effects can be increased when Hexobarbital is combined with Osanetant. Approved Hydrocodone Osanetant may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. Approved, Illicit Hydromorphone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Osanetant. Approved, Illicit Hydroxyamphetamine Osanetant may decrease the stimulatory activities of Hydroxyamphetamine. Approved Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Osanetant. Approved Iloperidone The risk or severity of adverse effects can be increased when Iloperidone is combined with Osanetant. Approved Imipramine The risk or severity of adverse effects can be increased when Imipramine is combined with Osanetant. Approved Indalpine The risk or severity of adverse effects can be increased when Osanetant is combined with Indalpine. Investigational, Withdrawn Indiplon The risk or severity of adverse effects can be increased when Osanetant is combined with Indiplon. Investigational Iofetamine I-123 Osanetant may decrease the stimulatory activities of Iofetamine I-123. Approved Isocarboxazid The therapeutic efficacy of Osanetant can be increased when used in combination with Isocarboxazid. Approved Isoflurane The risk or severity of adverse effects can be increased when Isoflurane is combined with Osanetant. Approved, Vet Approved Ketamine The risk or severity of adverse effects can be increased when Ketamine is combined with Osanetant. Approved, Vet Approved Ketazolam The risk or severity of adverse effects can be increased when Ketazolam is combined with Osanetant. Approved Ketobemidone The risk or severity of adverse effects can be increased when Osanetant is combined with Ketobemidone. Approved, Investigational Lamotrigine The risk or severity of adverse effects can be increased when Lamotrigine is combined with Osanetant. Approved, Investigational Levetiracetam The risk or severity of adverse effects can be increased when Levetiracetam is combined with Osanetant. Approved, Investigational Levobupivacaine The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Osanetant. Approved, Investigational Levocabastine The risk or severity of adverse effects can be increased when Osanetant is combined with Levocabastine. Approved, Investigational Levocetirizine The risk or severity of adverse effects can be increased when Levocetirizine is combined with Osanetant. Approved Levodopa The risk or severity of adverse effects can be increased when Levodopa is combined with Osanetant. Approved Levomethadyl Acetate The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Osanetant. Approved, Investigational Levomilnacipran The risk or severity of adverse effects can be increased when Osanetant is combined with Levomilnacipran. Approved, Investigational Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Osanetant. Approved Lidocaine The risk or severity of adverse effects can be increased when Lidocaine is combined with Osanetant. Approved, Vet Approved Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Osanetant. Approved, Investigational Lisdexamfetamine Osanetant may decrease the stimulatory activities of Lisdexamfetamine. Approved, Investigational Lithium Lithium may increase the neurotoxic activities of Osanetant. Approved Lofentanil The risk or severity of adverse effects can be increased when Osanetant is combined with Lofentanil. Illicit Lofexidine The therapeutic efficacy of Osanetant can be increased when used in combination with Lofexidine. Approved, Investigational Loprazolam The risk or severity of adverse effects can be increased when Osanetant is combined with Loprazolam. Experimental Loratadine The risk or severity of adverse effects can be increased when Loratadine is combined with Osanetant. Approved, Investigational Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Osanetant. Approved Lorcaserin The risk or severity of adverse effects can be increased when Lorcaserin is combined with Osanetant. Approved Lormetazepam The risk or severity of adverse effects can be increased when Osanetant is combined with Lormetazepam. Approved Loxapine The risk or severity of adverse effects can be increased when Loxapine is combined with Osanetant. Approved Lurasidone The risk or severity of adverse effects can be increased when Lurasidone is combined with Osanetant. Approved, Investigational Magnesium sulfate The therapeutic efficacy of Osanetant can be increased when used in combination with Magnesium sulfate. Approved, Investigational, Vet Approved Maprotiline The risk or severity of adverse effects can be increased when Maprotiline is combined with Osanetant. Approved, Investigational Mebicar The risk or severity of adverse effects can be increased when Osanetant is combined with Mebicar. Experimental Meclizine The risk or severity of adverse effects can be increased when Meclizine is combined with Osanetant. Approved Medazepam The risk or severity of adverse effects can be increased when Osanetant is combined with Medazepam. Experimental Medetomidine The risk or severity of adverse effects can be increased when Osanetant is combined with Medetomidine. Vet Approved Melatonin The risk or severity of adverse effects can be increased when Melatonin is combined with Osanetant. Approved, Nutraceutical, Vet Approved Melperone The risk or severity of adverse effects can be increased when Osanetant is combined with Melperone. Approved, Investigational Mephedrone Osanetant may decrease the stimulatory activities of Mephedrone. Investigational Mephentermine Osanetant may decrease the stimulatory activities of Mephentermine. Approved Mepivacaine The risk or severity of adverse effects can be increased when Mepivacaine is combined with Osanetant. Approved, Vet Approved Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Osanetant. Approved, Illicit Meptazinol The risk or severity of adverse effects can be increased when Osanetant is combined with Meptazinol. Experimental Mequitazine Osanetant may increase the arrhythmogenic activities of Mequitazine. Approved Mesoridazine The risk or severity of adverse effects can be increased when Mesoridazine is combined with Osanetant. Approved, Investigational Metaxalone The risk or severity of adverse effects can be increased when Metaxalone is combined with Osanetant. Approved Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Osanetant. Approved Methadyl Acetate The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Osanetant. Approved, Illicit Methamphetamine Osanetant may decrease the stimulatory activities of Methamphetamine. Approved, Illicit Methapyrilene The risk or severity of adverse effects can be increased when Methapyrilene is combined with Osanetant. Withdrawn Methaqualone The risk or severity of adverse effects can be increased when Methaqualone is combined with Osanetant. Illicit, Withdrawn Methocarbamol The risk or severity of adverse effects can be increased when Methocarbamol is combined with Osanetant. Approved, Vet Approved Methohexital The risk or severity of adverse effects can be increased when Methohexital is combined with Osanetant. Approved Methotrimeprazine Osanetant may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. Approved, Investigational Methoxyflurane The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Osanetant. Approved, Investigational, Vet Approved Methoxyphenamine Osanetant may decrease the stimulatory activities of Methoxyphenamine. Experimental Methsuximide The risk or severity of adverse effects can be increased when Methsuximide is combined with Osanetant. Approved Methylecgonine The risk or severity of adverse effects can be increased when Methylecgonine is combined with Osanetant. Experimental Methylphenidate The risk or severity of adverse effects can be increased when Osanetant is combined with Methylphenidate. Approved, Investigational Methylphenobarbital The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Osanetant. Approved Metoclopramide The risk or severity of adverse effects can be increased when Metoclopramide is combined with Osanetant. Approved, Investigational Metyrosine Osanetant may increase the sedative activities of Metyrosine. Approved Midazolam The risk or severity of adverse effects can be increased when Midazolam is combined with Osanetant. Approved, Illicit Midomafetamine Osanetant may decrease the stimulatory activities of Midomafetamine. Experimental, Illicit, Investigational Milnacipran The risk or severity of adverse effects can be increased when Osanetant is combined with Milnacipran. Approved, Investigational Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Osanetant. Approved, Investigational Mirtazapine Osanetant may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. Approved MMDA Osanetant may decrease the stimulatory activities of MMDA. Experimental, Illicit Moclobemide The risk or severity of adverse effects can be increased when Moclobemide is combined with Osanetant. Approved, Investigational Molindone The risk or severity of adverse effects can be increased when Molindone is combined with Osanetant. Approved Morphine The risk or severity of adverse effects can be increased when Morphine is combined with Osanetant. Approved, Investigational Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Osanetant. Approved, Investigational Nalbuphine The risk or severity of adverse effects can be increased when Nalbuphine is combined with Osanetant. Approved Naratriptan The risk or severity of adverse effects can be increased when Naratriptan is combined with Osanetant. Approved, Investigational Nefazodone The risk or severity of adverse effects can be increased when Osanetant is combined with Nefazodone. Approved, Withdrawn Nitrazepam The risk or severity of adverse effects can be increased when Nitrazepam is combined with Osanetant. Approved Nitrous oxide The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Osanetant. Approved, Vet Approved Nordazepam The risk or severity of adverse effects can be increased when Osanetant is combined with Nordazepam. Approved Norflurane The risk or severity of adverse effects can be increased when Osanetant is combined with Norflurane. Approved, Investigational Normethadone The risk or severity of adverse effects can be increased when Osanetant is combined with Normethadone. Approved, Illicit Nortriptyline The risk or severity of adverse effects can be increased when Nortriptyline is combined with Osanetant. Approved Olanzapine The risk or severity of adverse effects can be increased when Olanzapine is combined with Osanetant. Approved, Investigational Olopatadine The risk or severity of adverse effects can be increased when Olopatadine is combined with Osanetant. Approved Ondansetron The risk or severity of adverse effects can be increased when Ondansetron is combined with Osanetant. Approved Opium The risk or severity of adverse effects can be increased when Osanetant is combined with Opium. Approved, Illicit Orphenadrine Osanetant may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. Approved Oxazepam The risk or severity of adverse effects can be increased when Oxazepam is combined with Osanetant. Approved Oxprenolol The risk or severity of adverse effects can be increased when Oxprenolol is combined with Osanetant. Approved Oxybuprocaine The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Osanetant. Approved, Investigational Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Osanetant. Approved, Illicit, Investigational Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Osanetant. Approved, Investigational, Vet Approved Paliperidone The risk or severity of adverse effects can be increased when Paliperidone is combined with Osanetant. Approved Paraldehyde Osanetant may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. Approved, Investigational Paroxetine The risk or severity of adverse effects can be increased when Osanetant is combined with Paroxetine. Approved, Investigational Penfluridol The risk or severity of adverse effects can be increased when Osanetant is combined with Penfluridol. Experimental Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Osanetant. Approved, Vet Approved Pentobarbital The risk or severity of adverse effects can be increased when Pentobarbital is combined with Osanetant. Approved, Investigational, Vet Approved Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Osanetant. Approved Perazine The risk or severity of adverse effects can be increased when Osanetant is combined with Perazine. Approved, Investigational Perospirone The risk or severity of adverse effects can be increased when Osanetant is combined with Perospirone. Approved Perphenazine The risk or severity of adverse effects can be increased when Perphenazine is combined with Osanetant. Approved Pethidine The risk or severity of adverse effects can be increased when Pethidine is combined with Osanetant. Approved Phenazocine The risk or severity of adverse effects can be increased when Osanetant is combined with Phenazocine. Experimental Phenelzine The risk or severity of adverse effects can be increased when Phenelzine is combined with Osanetant. Approved Phenibut The risk or severity of adverse effects can be increased when Osanetant is combined with Phenibut. Experimental Phenobarbital The risk or severity of adverse effects can be increased when Phenobarbital is combined with Osanetant. Approved, Investigational Phenoperidine The risk or severity of adverse effects can be increased when Osanetant is combined with Phenoperidine. Experimental Phenoxyethanol The risk or severity of adverse effects can be increased when Osanetant is combined with Phenoxyethanol. Approved Phentermine Osanetant may decrease the stimulatory activities of Phentermine. Approved, Illicit Phenytoin The risk or severity of adverse effects can be increased when Phenytoin is combined with Osanetant. Approved, Vet Approved Pimozide The risk or severity of adverse effects can be increased when Pimozide is combined with Osanetant. Approved Pipamperone The risk or severity of adverse effects can be increased when Osanetant is combined with Pipamperone. Approved, Investigational Pipotiazine The risk or severity of adverse effects can be increased when Pipotiazine is combined with Osanetant. Approved, Investigational Piritramide The risk or severity of adverse effects can be increased when Osanetant is combined with Piritramide. Approved, Investigational Pizotifen The risk or severity of adverse effects can be increased when Pizotifen is combined with Osanetant. Approved Pomalidomide The risk or severity of adverse effects can be increased when Pomalidomide is combined with Osanetant. Approved Pramipexole Osanetant may increase the sedative activities of Pramipexole. Approved, Investigational Pramocaine The risk or severity of adverse effects can be increased when Osanetant is combined with Pramocaine. Approved Prazepam The risk or severity of adverse effects can be increased when Prazepam is combined with Osanetant. Approved, Illicit Pregabalin The therapeutic efficacy of Osanetant can be increased when used in combination with Pregabalin. Approved, Illicit, Investigational Prilocaine The risk or severity of adverse effects can be increased when Prilocaine is combined with Osanetant. Approved Primidone The risk or severity of adverse effects can be increased when Primidone is combined with Osanetant. Approved, Vet Approved Procaine The risk or severity of adverse effects can be increased when Procaine is combined with Osanetant. Approved, Investigational, Vet Approved Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Osanetant. Approved, Investigational Prochlorperazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Osanetant. Approved, Vet Approved Promazine The risk or severity of adverse effects can be increased when Promazine is combined with Osanetant. Approved, Vet Approved Promethazine The risk or severity of adverse effects can be increased when Promethazine is combined with Osanetant. Approved, Investigational Propanidid The risk or severity of adverse effects can be increased when Osanetant is combined with Propanidid. Experimental Proparacaine The risk or severity of adverse effects can be increased when Proparacaine is combined with Osanetant. Approved, Vet Approved Propofol The risk or severity of adverse effects can be increased when Propofol is combined with Osanetant. Approved, Investigational, Vet Approved Propoxycaine The risk or severity of adverse effects can be increased when Osanetant is combined with Propoxycaine. Approved Protriptyline The risk or severity of adverse effects can be increased when Protriptyline is combined with Osanetant. Approved Proxibarbal The risk or severity of adverse effects can be increased when Osanetant is combined with Proxibarbal. Experimental PSD502 The risk or severity of adverse effects can be increased when Osanetant is combined with PSD502. Investigational Pseudoephedrine Osanetant may decrease the stimulatory activities of Pseudoephedrine. Approved Quazepam The risk or severity of adverse effects can be increased when Quazepam is combined with Osanetant. Approved, Illicit Quetiapine The risk or severity of adverse effects can be increased when Quetiapine is combined with Osanetant. Approved Quinagolide The therapeutic efficacy of Quinagolide can be decreased when used in combination with Osanetant. Approved, Investigational Quinisocaine The risk or severity of adverse effects can be increased when Osanetant is combined with Quinisocaine. Experimental Raclopride The risk or severity of adverse effects can be increased when Osanetant is combined with Raclopride. Investigational Ramelteon The risk or severity of adverse effects can be increased when Ramelteon is combined with Osanetant. Approved, Investigational Rasagiline The risk or severity of adverse effects can be increased when Rasagiline is combined with Osanetant. Approved Remifentanil The risk or severity of adverse effects can be increased when Remifentanil is combined with Osanetant. Approved Remoxipride The risk or severity of adverse effects can be increased when Remoxipride is combined with Osanetant. Approved, Withdrawn Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Osanetant. Approved, Investigational Risperidone The risk or severity of adverse effects can be increased when Risperidone is combined with Osanetant. Approved, Investigational Ritanserin The risk or severity of adverse effects can be increased when Osanetant is combined with Ritanserin. Investigational Ritobegron Osanetant may decrease the stimulatory activities of Ritobegron. Investigational Rizatriptan The risk or severity of adverse effects can be increased when Rizatriptan is combined with Osanetant. Approved Romifidine The risk or severity of adverse effects can be increased when Osanetant is combined with Romifidine. Vet Approved Ropinirole Osanetant may increase the sedative activities of Ropinirole. Approved, Investigational Ropivacaine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Osanetant. Approved Rotigotine Osanetant may increase the sedative activities of Rotigotine. Approved Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Osanetant. Approved Scopolamine The risk or severity of adverse effects can be increased when Scopolamine is combined with Osanetant. Approved, Investigational Secobarbital The risk or severity of adverse effects can be increased when Secobarbital is combined with Osanetant. Approved, Vet Approved Selegiline The risk or severity of adverse effects can be increased when Selegiline is combined with Osanetant. Approved, Investigational, Vet Approved Sepranolone The risk or severity of adverse effects can be increased when Osanetant is combined with Sepranolone. Investigational Sertindole The risk or severity of adverse effects can be increased when Osanetant is combined with Sertindole. Approved, Investigational, Withdrawn Sertraline The risk or severity of adverse effects can be increased when Osanetant is combined with Sertraline. Approved Sevoflurane The risk or severity of adverse effects can be increased when Sevoflurane is combined with Osanetant. Approved, Vet Approved Sodium oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Osanetant. Approved Stiripentol The risk or severity of adverse effects can be increased when Stiripentol is combined with Osanetant. Approved Sufentanil The risk or severity of adverse effects can be increased when Sufentanil is combined with Osanetant. Approved, Investigational Sulpiride Osanetant may increase the antipsychotic activities of Sulpiride. Approved, Investigational Sultopride The risk or severity of adverse effects can be increased when Osanetant is combined with Sultopride. Experimental Sumatriptan The risk or severity of adverse effects can be increased when Sumatriptan is combined with Osanetant. Approved, Investigational Suvorexant Osanetant may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. Approved, Investigational Tandospirone The risk or severity of adverse effects can be increased when Osanetant is combined with Tandospirone. Investigational Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Osanetant. Approved Tasimelteon The risk or severity of adverse effects can be increased when Tasimelteon is combined with Osanetant. Approved, Investigational Tedizolid Phosphate The risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Osanetant. Approved Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Osanetant. Approved, Investigational Tetrabenazine The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Osanetant. Approved, Investigational Tetracaine The risk or severity of adverse effects can be increased when Osanetant is combined with Tetracaine. Approved, Vet Approved Tetrahydropalmatine The risk or severity of adverse effects can be increased when Osanetant is combined with Tetrahydropalmatine. Investigational Tetrodotoxin The risk or severity of adverse effects can be increased when Osanetant is combined with Tetrodotoxin. Investigational Thalidomide Osanetant may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. Approved, Investigational, Withdrawn Thiamylal The risk or severity of adverse effects can be increased when Thiamylal is combined with Osanetant. Approved, Vet Approved Thiopental The risk or severity of adverse effects can be increased when Thiopental is combined with Osanetant. Approved, Vet Approved Thioridazine The risk or severity of adverse effects can be increased when Thioridazine is combined with Osanetant. Approved, Withdrawn Thiothixene The risk or severity of adverse effects can be increased when Thiothixene is combined with Osanetant. Approved Tiagabine The risk or severity of adverse effects can be increased when Tiagabine is combined with Osanetant. Approved, Investigational Tiapride The risk or severity of adverse effects can be increased when Osanetant is combined with Tiapride. Approved, Investigational Tiletamine The risk or severity of adverse effects can be increased when Osanetant is combined with Tiletamine. Vet Approved Tilidine The risk or severity of adverse effects can be increased when Osanetant is combined with Tilidine. Experimental Tizanidine The risk or severity of adverse effects can be increased when Tizanidine is combined with Osanetant. Approved, Investigational Tolcapone The risk or severity of adverse effects can be increased when Tolcapone is combined with Osanetant. Approved, Withdrawn Topiramate The risk or severity of adverse effects can be increased when Topiramate is combined with Osanetant. Approved Tramadol The risk or severity of adverse effects can be increased when Tramadol is combined with Osanetant. Approved, Investigational Tranylcypromine The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Osanetant. Approved, Investigational Trazodone The risk or severity of adverse effects can be increased when Trazodone is combined with Osanetant. Approved, Investigational Triazolam The risk or severity of adverse effects can be increased when Triazolam is combined with Osanetant. Approved, Investigational Tricaine methanesulfonate The risk or severity of adverse effects can be increased when Osanetant is combined with Tricaine methanesulfonate. Vet Approved Trichloroethylene The risk or severity of adverse effects can be increased when Osanetant is combined with Trichloroethylene. Approved Trifluoperazine The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Osanetant. Approved, Investigational Trifluperidol The risk or severity of adverse effects can be increased when Osanetant is combined with Trifluperidol. Experimental Triflupromazine The risk or severity of adverse effects can be increased when Triflupromazine is combined with Osanetant. Approved, Vet Approved Trimipramine The risk or severity of adverse effects can be increased when Trimipramine is combined with Osanetant. Approved Triprolidine The risk or severity of adverse effects can be increased when Triprolidine is combined with Osanetant. Approved Valproic Acid The risk or severity of adverse effects can be increased when Valproic Acid is combined with Osanetant. Approved, Investigational Vemurafenib The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Osanetant. Approved Venlafaxine The risk or severity of adverse effects can be increased when Osanetant is combined with Venlafaxine. Approved Veralipride The risk or severity of adverse effects can be increased when Osanetant is combined with Veralipride. Experimental Vigabatrin The risk or severity of adverse effects can be increased when Vigabatrin is combined with Osanetant. Approved Vilazodone The risk or severity of adverse effects can be increased when Vilazodone is combined with Osanetant. Approved Vinyl ether The risk or severity of adverse effects can be increased when Osanetant is combined with Vinyl ether. Experimental Vortioxetine The risk or severity of adverse effects can be increased when Osanetant is combined with Vortioxetine. Approved, Investigational Xenon The risk or severity of adverse effects can be increased when Osanetant is combined with Xenon. Experimental Xylazine The risk or severity of adverse effects can be increased when Osanetant is combined with Xylazine. Vet Approved Zaleplon The risk or severity of adverse effects can be increased when Zaleplon is combined with Osanetant. Approved, Illicit, Investigational Ziconotide The risk or severity of adverse effects can be increased when Ziconotide is combined with Osanetant. Approved Zimelidine The risk or severity of adverse effects can be increased when Osanetant is combined with Zimelidine. Withdrawn Ziprasidone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Osanetant. Approved Zolazepam The risk or severity of adverse effects can be increased when Osanetant is combined with Zolazepam. Vet Approved Zolmitriptan The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Osanetant. Approved, Investigational Zolpidem Osanetant may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Approved Zonisamide The risk or severity of adverse effects can be increased when Zonisamide is combined with Osanetant. Approved, Investigational Zopiclone The risk or severity of adverse effects can be increased when Zopiclone is combined with Osanetant. Approved Zotepine The risk or severity of adverse effects can be increased when Osanetant is combined with Zotepine. Approved, Investigational, Withdrawn Zuclopenthixol The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Osanetant. Approved, Investigational - Food Interactions
- Not Available
References
- General References
- Kronenberg G, Berger P, Tauber RF, Bandelow B, Henkel V, Heuser I: Randomized, double-blind study of SR142801 (Osanetant). A novel neurokinin-3 (NK3) receptor antagonist in panic disorder with pre- and posttreatment cholecystokinin tetrapeptide (CCK-4) challenges. Pharmacopsychiatry. 2005 Jan;38(1):24-9. [PubMed:15706463]
- Kamali F: Osanetant Sanofi-Synthelabo. Curr Opin Investig Drugs. 2001 Jul;2(7):950-6. [PubMed:11757797]
- External Links
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.000154 mg/mL ALOGPS logP 6.47 ALOGPS logP 6.27 ChemAxon logS -6.6 ALOGPS pKa (Strongest Basic) 9.3 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 43.86 Å2 ChemAxon Rotatable Bond Count 8 ChemAxon Refractivity 172.73 m3·mol-1 ChemAxon Polarizability 66.11 Å3 ChemAxon Number of Rings 5 ChemAxon Bioavailability 0 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9486 Blood Brain Barrier + 0.9882 Caco-2 permeable + 0.5767 P-glycoprotein substrate Substrate 0.6866 P-glycoprotein inhibitor I Inhibitor 0.7694 P-glycoprotein inhibitor II Inhibitor 0.837 Renal organic cation transporter Inhibitor 0.5525 CYP450 2C9 substrate Non-substrate 0.8013 CYP450 2D6 substrate Non-substrate 0.6861 CYP450 3A4 substrate Substrate 0.7427 CYP450 1A2 substrate Non-inhibitor 0.9532 CYP450 2C9 inhibitor Non-inhibitor 0.9439 CYP450 2D6 inhibitor Inhibitor 0.5109 CYP450 2C19 inhibitor Non-inhibitor 0.8248 CYP450 3A4 inhibitor Non-inhibitor 0.703 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.7353 Ames test Non AMES toxic 0.7977 Carcinogenicity Non-carcinogens 0.8292 Biodegradation Not ready biodegradable 0.994 Rat acute toxicity 2.8030 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9523 hERG inhibition (predictor II) Inhibitor 0.8584
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as 1-benzoylpiperidines. These are compounds containing a piperidine ring substituted at the 1-position with a benzoyl group.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Benzoyl derivatives
- Direct Parent
- 1-benzoylpiperidines
- Alternative Parents
- N-benzoylpiperidines / Phenylpiperidines / Phenylbutylamines / Benzamides / Dichlorobenzenes / Aralkylamines / Aryl chlorides / Tertiary carboxylic acid amides / Acetamides / Trialkylamines show 7 more
- Substituents
- N-benzoylpiperidine / 1-benzoylpiperidine / Phenylpiperidine / Phenylbutylamine / N-acyl-piperidine / Benzamide / Benzoic acid or derivatives / 1,2-dichlorobenzene / Aralkylamine / Chlorobenzene show 25 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Tachykinin receptor activity
- Specific Function
- This is a receptor for the tachykinin neuropeptide neuromedin-K (neurokinin B). It is associated with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order...
- Gene Name
- TACR3
- Uniprot ID
- P29371
- Uniprot Name
- Neuromedin-K receptor
- Molecular Weight
- 52201.35 Da
References
- Tian G, Wilkins D, Scott CW: Neurokinin-3 receptor-specific antagonists talnetant and osanetant show distinct mode of action in cellular Ca2+ mobilization but display similar binding kinetics and identical mechanism of binding in ligand cross-competition. Mol Pharmacol. 2007 Mar;71(3):902-11. Epub 2006 Dec 15. [PubMed:17172464]
Drug created on October 20, 2007 04:46 / Updated on June 02, 2018 07:36